Health and Healthcare

Novartis : NVS

All Novartis Articles

134 Articles

Douglas A. McIntyre | Jul 22, 2009 at 4:01 AM EDT

The Next Blockbuster Drugs: A $170 Billion Opportunity

Safety and efficacy data are critical to drug candidates. But what really makes a potential drug attractive is strong top-line…

Douglas A. McIntyre | Jul 17, 2009 at 7:14 AM EDT

Top 10 Analyst Upgrades and Downgrades (CME, DRI, ICE, MYGN, NVS, ALXN, MDRX, NNI, NOK)

There were many analyst calls this morning, but the problem is that most were on smaller companies or were by…

Douglas A. McIntyre | Jul 8, 2009 at 9:47 AM EDT

BioHealth Business Daily (AMGN, NVS, AMLN, LLY, ALKS, NVO, LLY, VICL, SCLN, ARNA)

These are some of the top stories affecting key drug and biotech stocks that are covered with more in-depth details…

Douglas A. McIntyre | Jul 8, 2009 at 8:10 AM EDT

Day Trader Alerts (AMGN, NVS, MSCS, DRYS, ARYX, XNPT, ARNA, BPZ)

These are some of the top stocks for day traders and active traders to watch based on pre-market and after-hours…

Douglas A. McIntyre | Jun 29, 2009 at 2:54 AM EDT

Media Digest 6/29/2009

Reuters: GM will accept product liability on cars it has built in the past. Reuters: Obama could consider a second…

Douglas A. McIntyre | Jun 25, 2009 at 11:31 AM EDT

Generic Biotech Drug Approval in Japan, Implications in U.S. and Abroad (NVS, PFE, AZN, AMGN, GENZ, GILD, CELG)

Novartis AG (NYSE: NVS) shares are at session highs and well of the lows of the day in the early…

Douglas A. McIntyre | Sep 23, 2008 at 6:06 AM EDT

Early Bird Analyst Upgrades (NLY, ATML, DWA, NVS, PRM, SSCC, SNWL)

These are not all of the upgrades and positive analyst calls on Wall Street this morning, but these are the…

Douglas A. McIntyre | Aug 6, 2008 at 6:39 AM EDT

Top Pre-Market Analyst Upgrades & Downgrades (ELN, ESLT, LLNW, RDC, SLW, AIG, EAT, ENTR, HNT, INAP, NVS, OEH, PACR, TI )

Upgrades and Positive Calls: Elan (ELN) Raised to Equal-weight at Lehman. Elbit Systems (ESLT) Raised to Buy at UBS. Limelight…

Douglas A. McIntyre | Jun 2, 2008 at 6:37 AM EDT

Top 10 Pre-Market Analyst Calls (ANR, NILE, ENER, IFX, LH, NVS, SOV, TSCO, WY, YGE)

These are ten of the analyst calls we are focusing on this Monday morning in pre-market trading: Alpha Natural Resources…

Douglas A. McIntyre | May 9, 2008 at 6:37 AM EDT

Top 10 Pre-Market Analyst Calls (ABT, AEIS, AMSC, CREE, DRS, FORM, RAIL, NVS, PNSN, SOV)

These are ten of the impact analyst calls we are seeing this Friday morning: Abbott Labs (NYSE: ABT) started as…

Douglas A. McIntyre | Jan 14, 2008 at 12:33 PM EST

Can Genentech Buck Its Long-Term Slide? (DNA, BIIB, NVS, OSIP, AMGN, BBH)

Genentech (NYSE: DNA) is set to report earnings after the close today. First Call has estimates pegged at $0.67 EPS…

Douglas A. McIntyre | Jun 20, 2007 at 4:37 PM EDT

Biotech Implosion: Coley Pharmaceutical Group (COLY)

Shares of microcap biotech Coley Pharmaceutical Group (COLY-NASDAQ) saw shares get pounded late on Wednesday afternoon. Right before 2:00 PM…

Douglas A. McIntyre | Jun 15, 2007 at 6:42 AM EDT

Pre-Market Stock News (June 15, 2007)

(ADBE) Adobe trading down 1% after beating earnings but issuing in-line guidance.(BBW) Build-a-Bear lowered guidance; stock down almost 15%.(CROX) CROCS…

Douglas A. McIntyre | Jun 12, 2007 at 5:53 PM EDT

Cramer’s Picks & Pans in Pharmaceuticals

Stock Tickers: MRK, PFE, JNJ, GSK, SGP, LLY, WYE, NVS, NVO On tonight’s MAD MONEY on CNBC, Jim Cramer said…

1 … 7 8 9

Novartis : NVS

All Novartis Articles

The Next Blockbuster Drugs: A $170 Billion Opportunity

Top 10 Analyst Upgrades and Downgrades (CME, DRI, ICE, MYGN, NVS, ALXN, MDRX, NNI, NOK)

BioHealth Business Daily (AMGN, NVS, AMLN, LLY, ALKS, NVO, LLY, VICL, SCLN, ARNA)

Day Trader Alerts (AMGN, NVS, MSCS, DRYS, ARYX, XNPT, ARNA, BPZ)

Media Digest 6/29/2009

Generic Biotech Drug Approval in Japan, Implications in U.S. and Abroad (NVS, PFE, AZN, AMGN, GENZ, GILD, CELG)

Early Bird Analyst Upgrades (NLY, ATML, DWA, NVS, PRM, SSCC, SNWL)

Top Pre-Market Analyst Upgrades & Downgrades (ELN, ESLT, LLNW, RDC, SLW, AIG, EAT, ENTR, HNT, INAP, NVS, OEH, PACR, TI )

Top 10 Pre-Market Analyst Calls (ANR, NILE, ENER, IFX, LH, NVS, SOV, TSCO, WY, YGE)

Top 10 Pre-Market Analyst Calls (ABT, AEIS, AMSC, CREE, DRS, FORM, RAIL, NVS, PNSN, SOV)

Can Genentech Buck Its Long-Term Slide? (DNA, BIIB, NVS, OSIP, AMGN, BBH)

Biotech Implosion: Coley Pharmaceutical Group (COLY)

Pre-Market Stock News (June 15, 2007)

Cramer’s Picks & Pans in Pharmaceuticals

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

This High-Yield ETF Combines Bond Investing With Emerging Market Currencies

SoFi Stock Could Jump 26% as Market Overreacts to One Soft Segment

52% of Americans Are Building Wealth While Ignoring Their Greatest Risk

3 Reasons Retirees Should Not Enroll in Medicare Advantage for 2026

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

This High-Yield ETF Combines Bond Investing With Emerging Market Currencies

Novartis : NVS

All Novartis Articles

The Next Blockbuster Drugs: A $170 Billion Opportunity

Top 10 Analyst Upgrades and Downgrades (CME, DRI, ICE, MYGN, NVS, ALXN, MDRX, NNI, NOK)

BioHealth Business Daily (AMGN, NVS, AMLN, LLY, ALKS, NVO, LLY, VICL, SCLN, ARNA)

Day Trader Alerts (AMGN, NVS, MSCS, DRYS, ARYX, XNPT, ARNA, BPZ)

Media Digest 6/29/2009

Generic Biotech Drug Approval in Japan, Implications in U.S. and Abroad (NVS, PFE, AZN, AMGN, GENZ, GILD, CELG)

Early Bird Analyst Upgrades (NLY, ATML, DWA, NVS, PRM, SSCC, SNWL)

Top Pre-Market Analyst Upgrades & Downgrades (ELN, ESLT, LLNW, RDC, SLW, AIG, EAT, ENTR, HNT, INAP, NVS, OEH, PACR, TI )

Top 10 Pre-Market Analyst Calls (ANR, NILE, ENER, IFX, LH, NVS, SOV, TSCO, WY, YGE)

Top 10 Pre-Market Analyst Calls (ABT, AEIS, AMSC, CREE, DRS, FORM, RAIL, NVS, PNSN, SOV)

Can Genentech Buck Its Long-Term Slide? (DNA, BIIB, NVS, OSIP, AMGN, BBH)

Biotech Implosion: Coley Pharmaceutical Group (COLY)

Pre-Market Stock News (June 15, 2007)

Cramer’s Picks & Pans in Pharmaceuticals

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

This High-Yield ETF Combines Bond Investing With Emerging Market Currencies

SoFi Stock Could Jump 26% as Market Overreacts to One Soft Segment

Featured Reads

52% of Americans Are Building Wealth While Ignoring Their Greatest Risk

3 Reasons Retirees Should Not Enroll in Medicare Advantage for 2026